Breast cancer treatment combination and dose improves survival in people with inherited BRCA1 and BRCA2 mutations
https://www.facingourrisk.org/XRAY/PARTNER-trial-BRCA
Full article: https://www.nature.com/articles/s41467-025-59151-0
Treatment before surgery with a combination of targeted therapy and chemotherapy resulted in longer survival for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. The study evaluated a new dosing strategy that made it possible to safely combine Lynparza (olaparib) and chemotherapy (carboplatin). (Posted 8/31/25)
Questions To Ask Your Health Care Provider
- Does my cancer test positive for a BRCA1 or BRCA2 mutation?
- Should I have genetic testing to determine whether I have an inherited mutation?
- Do you recommend neoadjuvant therapy? If so, what kind?
- Is Lynparza plus chemotherapy an option for me as standard treatment or through a clinical trial?
- What are the potential risks and benefits associated with my recommended therapy?
Open Clinical Trials
The following are studies looking at new treatments for people with metastatic TNBC.
- NCT03606967: Testing the Addition of an Individual Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer. This study evaluates how well the combination of chemotherapy, immunotherapy and targeted therapy when used with or without a vaccine made specifically for each patient.
- NCT04468061: Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic TNBC. This early phase study looks at the safety and effectiveness of Trodelvy with or without pembrolizumab for patients with TNBC that has spread to other parts of the body.
- NCT04020575: Using a Type of Immunotherapy Called CAR-T to Treat Metastatic Triple-Negative Breast Cancer. This study measures the safety and effectiveness of a treatment made from the patient's cancer when used for certain types of metastatic breast cancer.
- NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent TNBC (InCITe). This project studies how well the combination of avelumab with liposomal doxorubicin works with or without binimetinib. It also studies the combination of avelumab with sacituzumab govitecan to treat metastatic TNBC that has recurred.
- NCT04837209. Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR). This research study is looking to see whether the combination of dostarlimab and niraparib plus radiation therapy is safe and effective for participants with metastatic triple-negative breast cancer.
- NCT05081492: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer. This study identifies the safety, side effects, and best dose of a drug called CF33-hNIS-antiPDL1 (a virus that is designed to attack and kill cancer cells) for treating patients with metastatic triple negative breast cancer.
Several other clinical trials for treating patients with metastatic TNBC can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.